Research Foundation News

February 26, 2020

Support grows for technology aimed at turning bad fat to good fat, to treat millions with obesity, diabetes

WEST LAFAYETTE, Ind. – A significant investment from a Purdue University alumnus and his wife will help further develop technology aimed at treating obesity and diabetes by turning bad fat into good fat inside the body.

David Campbell, a 1978 graduate from Purdue’s Krannert School of Management, and his wife, Michelle, are residents of Old Hickory, Tennessee. 

They have committed the support to Adipo Therapeutics LLC, a Purdue-based startup, which is developing a unique treatment approach for people struggling with obesity and diabetes. This treatment could improve the lives of the more than 2 billion people worldwide who are overweight, and the 463 million suffering from diabetes.  

Meng Deng, an assistant professor in Purdue’s Department of Agricultural and Biological Engineering, Weldon School of Biomedical Engineering, and School of Materials Engineering, founded Adipo.

fat-cells This image shows bioengineered nanoparticles inducing the conversion of bad fat. (Image provided by Alexander M. Gokan) Download image


He had support from the Purdue Foundry, an entrepreneurship and commercialization hub housed in the Convergence Center for Innovation and Collaboration in Purdue’s Discovery Park District.

Adipo Therapeutics and Meng Deng's work represent the tangible promise of hope,” Campbell said. “Deng, Karen Wurster, Purdue Research Foundation’s Wade Lange and the support of the foundation provide the ideal combination of intellect, commercial experience and institutional reputation to convert the promise to reality.”

The Adipo team uses an engineered polymeric nanoparticluate system in a product that could be first to convert energy-storing white (bad) fat to energy-burning brown (good) fat through regulation of Notch signaling pathway. Deng said this holds great promise to fill the niche by providing a unique safe and effective solution for the millions of Type 2 diabetic obese patients.

Technology used by Adipo has been licensed through the Purdue Research Foundation Office of Technology Commercialization.

Adipo integrates two platform technologies to develop polymer-based nanotherapeutics that act directly on fat tissue to provide sustained weight loss and improved blood sugar control. A video about Adipo is available at

“This investment is crucial to fund our efforts to further develop our technology for translation, and recruit the right mix of talents for our Adipo team,” Deng said. “We have recently hired Karen Wurster as our business advisor, bringing with her over 20 years of diabetes and obesity experience to Adipo, and will continue to build our team in the first half of this year. It is an exciting time for Adipo and we are fortunate to have the continuing support from the Purdue Foundry and Purdue entrepreneurial ecosystem.”

Diabetes and obesity are contributing factors to developing comorbidities including heart disease, stroke, high blood pressure, and kidney disease. Removing excess fat through nanoparticle injections would likely decrease the odds of developing these complications.

“Obesity is a complex and chronic disease with many complications,” said Dr. Shannon Oates, a clinical consultant for Adipo. “I have worked for over a quarter of a century as a physician helping care for people who have diabetes or are at risk for obesity complications. Any addition to our toolbox to help treat this disease will be greatly applauded. The current epidemic of obese and overweight people in the U.S. and around the world is a major crisis and deserves all possible therapies.”

Adipo is seeking additional funding to support continued development, clinical translation, and submission to the Food and Drug Administration. The company is seeking partnerships with firms and pharmaceutical companies interested in the technology.

About Adipo Therapeutics LLC

Adipo Therapeutics is developing a disruptive technology platform composed of polymer-based nanoparticulate drug delivery systems to induce adipocyte browning as a safe and effective therapeutic solution to treat obesity. This innovation combines the recent discovery of the role played by Notch signaling in adipocyte plasticity with advances in polymer-based drug delivery. This technology offers several unique value propositions including sustainable weight loss, improved glucose homeostasis and systemic metabolism, and minimized off-target side effects. Such an enabling technology platform can also be readily adapted to treat a broad spectrum of diseases such as fatty liver disease and atherosclerosis.          

About Purdue Foundry

The Purdue Foundry is an entrepreneurship and commercialization hub whose professionals help Purdue innovators create startups. The Purdue Foundry is housed in the Convergence Center for Innovation and Collaboration in Discovery Park District, located on the west side of the Purdue campus. The Purdue Foundry is managed by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at

Writer: Chris Adam, 765-588-3341, 
Sources: Meng Deng,

Karen Wurster,


Research Foundation News

Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, (765) 494-4600

© 2015-20 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by Office of Strategic Communications

Trouble with this page? Disability-related accessibility issue? Please contact News Service at